What is OTLK's current stock price?

OTLK (Outlook Therapeutics, Inc.) is currently trading at $0.31 with a market cap of $12.7M.

What sector is Outlook Therapeutics, Inc. in?

Outlook Therapeutics, Inc. (OTLK) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is OTLK a good stock to buy?

Analysts have a Hold consensus on OTLK with a price target of $1.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

OTLK Outlook Therapeutics, Inc.

Healthcare

$0.31-6.94%ClosedMarket Cap: $12.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.00

P/S

38.27

EV/EBITDA

121287.57

DCF Value

$1.70

FCF Yield

-178574461.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

-370.0%

Operating Margin

-18182.8%

Net Margin

-18297.5%

ROE

0.0%

ROA

-0.0%

ROIC

0.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$127.4K	$-4.5M	$—
Q1 null	$-1.2M	$-23.1M	$—
Q4 null	$-91.8K	$-13.3M	$—
FY null	$1.4M	$-62.4M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$1.00

Target (Median)

$1.00

Target Range

$1.00 - $1.00

0 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell

BTIGNeutral

2026-05-18

Ascendiant CapitalBuy

2026-03-11

HC Wainwright & Co.Neutral

2026-02-18

Chardan CapitalNeutral

2026-02-18

Chardan CapitalNeutral

2026-01-05

Trading Activity

Insider Trades

View All

Huang Andongdirector

SellFri Oct 03

Huang Andongdirector

SellFri Oct 03

HILZINGER KURT Jdirector

SellFri Oct 03

HILZINGER KURT Jdirector

SellFri Oct 03

Haller Julia Adirector

SellFri Oct 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.33

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Peers

COEP

CUE